Policy: MBP 114.0  
Section: Medical Benefit Pharmaceutical Policy  
Subject: Vimizim (elosulfase alfa)

I. Policy:  
Vimizim (elosulfase alfa)

II. Purpose/Objective:  
To provide a policy of coverage regarding Vimizim (elosulfase alfa)

III. Responsibility:  
A. Medical Directors  
B. Medical Management  
C. Pharmacy Department

IV. Required Definitions  
1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.  
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.  
3. Devised – the date the policy was implemented.  
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.  
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions  
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:  

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;  
b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;  
c. in accordance with current standards good medical treatment practiced by the general medical community;  
d. not primarily for the convenience of the Member, or the Member’s Health Care Provider; and  
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment  
Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:  

(i) the service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.  
(ii) the service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.  
(iii) the service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.
DESCRIPTION:
Vimizim (elosulfase alfa) acts to provide the exogenous enzyme GALNS that is taken up into the lysosomes and increased the catabolism of the GAGs KS and C6S.

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

Vimizim (elosulfase alfa) will be considered medically necessary when all of the following criteria are met:

- Prescription is written by a biochemical geneticist or metabolic physician; and
- Medical record documentation of:
  - Mucopolysaccharidosis IV A (MPS IVA, Morquio syndrome) including genetic testing confirmation; and
  - Age 5 years or greater; and
  - Insured individual’s weight dated within one month of the request; and
  - Baseline 6-minute walking distance and objective measures that will be used to judge clinical impact; and
  - Once weekly dosing

AUTHORIZATION DURATION
Initial approval will be for six (6) months. Subsequent approvals will also be for six (6) months. For reauthorization, the following criteria must be met:

Medical record documentation of:

- Improvement in six-minute walking distance from baseline or other objective evidence of benefit from the use of Vimizim; and
- Absence of hypersensitivity reaction(s) to the medication; and
- Insured individual's weight dated within one (1) month of the request.

LINE OF BUSINESS:
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 7/15/14

Reviewed: 11/2/2015, 10/26/16, 9/29/17, 8/30/18, 8/29/19